Bayer CEO Dekkers says price cuts threaten R&D

Bayer CEO Marijn Dekkers totted up a $2.7 billion price tag to research and develop the new anticoagulant Xarelto. And he's warning tight-fisted payers that the more they squeeze drug companies on product prices, the harder it will be to come up with important new treatments in the pipeline. "We need innovative pharmaceuticals more than ever, because so many known diseases still cannot be treated adequately, or at all, with medicines," Dekkers asserted as he warned that revenue is likely to stay largely flat in this financial environment. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.